There have been many significant treatment advancements in recent years, yet approximately 70 to 90 percent of women treated for ovarian cancer will relapse.

If you’ve been diagnosed with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer, the way forward may seem uncertain.

Participating in a TRINOVA research study is one of the options that may be available to you.

Amgen is the biotechnology company that is sponsoring these trials.